We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+26.51%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.37B
AUM Growth
-$51.4M
Cap. Flow
-$112M
Cap. Flow %
-4.71%
Top 10 Hldgs %
45.23%
Holding
88
New
8
Increased
6
Reduced
18
Closed
10

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$105M
2
ZYME icon
Zymeworks
ZYME
+$41.2M
3
IMVT icon
Immunovant
IMVT
+$32.2M
4
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$26.6M
5
NAMS icon
NewAmsterdam Pharma
NAMS
+$15.1M

Top Sells

Rank Stock Value
1
RLMD icon
Relmada Therapeutics
RLMD
+$76.9M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$73.7M
3
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$43.1M
4
NUVL
Nuvalent
NUVL
+$32.4M
5
EQRX
EQRx, Inc. Common Stock
EQRX
+$29.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
1
MoonLake Immunotherapeutics
MLTX
$1.57B
$228M 9.64%
21,751,284
– –
AXSM icon
2
Axsome Therapeutics
AXSM
$11.2B
$135M 5.71%
+1,755,000
New +$105M
RPTX
3
DELISTED
Repare Therapeutics
RPTX
$122M 5.15%
8,291,988
– –
KYMR icon
4
Kymera Therapeutics
KYMR
$8.51B
$117M 4.94%
4,692,604
– –
GHRS icon
5
GH Research
GHRS
$1.93B
$89.7M 3.79%
9,275,158
– –
FDMT icon
6
4D Molecular Therapeutics
FDMT
$532M
$89M 3.76%
4,007,413
– –
CGEM icon
7
Cullinan Oncology
CGEM
$1.01B
$79.2M 3.34%
7,509,059
– –
RVMD icon
8
Revolution Medicines
RVMD
$39.9B
$77.5M 3.27%
3,255,588
– –
PNT
9
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$66.9M 2.82%
9,177,748
+3,587,700
+64% +$26.6M
XOMA
10
DELISTED
Xoma
XOMA
$66.5M 2.8%
3,611,494
– –
RLAY icon
11
Relay Therapeutics
RLAY
$4.1B
$57.9M 2.44%
3,876,021
-463,500
-11% -$8.87M
CTIC
12
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$53M 2.24%
8,813,021
– –
ACRS icon
13
Aclaris Therapeutics
ACRS
$726M
$51.6M 2.18%
3,276,543
-700,000
-18% -$11.3M
XENE icon
14
Xenon Pharmaceuticals
XENE
$6.06B
$50.1M 2.12%
1,271,243
+370,148
+41% +$13.5M
CRNX icon
15
Crinetics Pharmaceuticals
CRNX
$8.84B
$50.1M 2.11%
2,736,613
-942,334
-26% -$16.6M
RCUS icon
16
Arcus Biosciences
RCUS
$3.55B
$47.6M 2.01%
2,303,520
-413,500
-15% -$11.4M
KURA icon
17
Kura Oncology
KURA
$800M
$47.2M 1.99%
3,800,983
+597,200
+19% +$8.68M
ZYME icon
18
Zymeworks
ZYME
$1.61B
$46.1M 1.95%
+5,870,000
New +$41.2M
MRUS
19
DELISTED
Merus
MRUS
$46.1M 1.94%
2,978,420
-466,000
-14% -$8.2M
IMVT icon
20
Immunovant
IMVT
$7.93B
$45.5M 1.92%
+2,561,000
New +$32.2M
IONS icon
21
Ionis Pharmaceuticals
IONS
$8.6B
$42.4M 1.79%
1,121,809
-1,751,144
-61% -$73.7M
ALLK
22
DELISTED
Allakos
ALLK
$42.2M 1.78%
5,006,921
– –
REPL icon
23
Replimune Group
REPL
$941M
$41.4M 1.75%
1,522,629
+596,100
+64% +$12.4M
IDYA icon
24
IDEAYA Biosciences
IDYA
$3.42B
$40.1M 1.69%
2,205,089
-1,089,770
-33% -$18.3M
SNDX icon
25
Syndax Pharmaceuticals
SNDX
$1.69B
$36.9M 1.56%
1,451,197
-346,888
-19% -$8.09M
1
2 3 4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2022 Portfolio in Review

As of Q4 2022, BVF Inc held 88 positions worth $2.37B, down 2.1% from $2.42B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

BVF Inc withdrew a net $112M in Q4 2022, closing 10 positions and reducing 18 holdings. Its most notable exit was Relmada Therapeutics, an estimated $76.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

Against the trend, BVF Inc opened a new position in Axsome Therapeutics worth $135M.

  • BVF Inc's largest Q4 2022 buy was Axsome Therapeutics: 1,755,000 shares worth $135M.
  • BVF Inc added most to POINT Biopharma Global Inc. Common Stock in Q4 2022, an estimated $26.6M increase.
  • BVF Inc's biggest Q4 2022 reduction was Ionis Pharmaceuticals, cutting an estimated $73.7M.
  • BVF Inc fully exited Relmada Therapeutics in Q4 2022, selling an estimated $76.9M.
  • BVF Inc's ten largest holdings make up 45% of its $2.37B portfolio in Q4 2022.
  • BVF Inc opened 8 new positions and closed 10 in Q4 2022.
  • BVF Inc's portfolio value fell 2.1% quarter-over-quarter to $2.37B.

Based on BVF Inc's 13F filing for Q4 2022, filed 14 Feb 2023.